secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001193125-24-197971
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma enters $150M ATM equity offering with TD Cowen as agent
---------------------------------------------------------------------------

- Amended Sales Agreement replaces Cowen and Company with TD Cowen as sole sales agent.
- Company may issue and sell up to $150M in ordinary shares at market prices via ATM offering.
- No shares were sold under the prior December 2023 sales agreement.
- TD Cowen receives up to 3% commission on gross sales; company has no obligation to sell.
- Sales may be made through an affiliate of TD Cowen; agreement terminable at will by either party.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524197971/0001193125-24-197971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524197971/d823291d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-197971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer